Zhou A, Din Y, Chen M
Shanghai Second Medical University.
Zhong Xi Yi Jie He Za Zhi. 1990 Jun;10(6):343-4, 324.
From 1986, the authors mainly used Modified Xiao-Jin Pills (MXJP) added with chemical treatment to cure patients in mid and late phase of gastric cancer after operation. 72 patients were verified as gastric cancer by pathological section and phases were divided according to TNM classification which was revised by the national cooperative group of gastric cancer in 1978. The patients were randomly divided into curative and control groups. The two groups were basically similar in sex, age, clinic pathological phase and operation. One month after operation, the two groups received the same treatment except that the control group did not take MXJP. The indexes of observation consisted of living rate, substance of tongue and 5 indexes of blood coagulation (AT-III, Fn, FA, VIII R:Ag and beta TG). The curative effects showed that MXJP could enhance gastric cancer patients living rate for 1, 1.5 and 2 years among which it was obvious for phase IV's gastric cancer patients to enhance 1 year's living rate (P less than 0.05), and lower the negative rate of substance of tongue (P less than 0.001). The indexes of AT-III, Fn FA and VIII R:Ag and beta TG of gastric cancer patients had changed for the better (P less than 0.05). The results showed that MXJP can enhance the capacity of body to antagonize coagulation fibrinolysis, remove blood stasis and further enhance the living rate of patients. MXJP has better curative effects of short term.
自1986年起，作者主要采用加用化疗的小金丸改良方（MXJP）治疗胃癌术后中晚期患者。72例患者经病理切片确诊为胃癌，并根据1978年全国胃癌协作组修订的TNM分类法进行分期。患者被随机分为治疗组和对照组。两组在性别、年龄、临床病理分期及手术方式上基本相似。术后1个月，两组接受相同治疗，对照组除外不服用MXJP。观察指标包括生存率、舌质及5项凝血指标（抗凝血酶III、纤维连接蛋白、纤维蛋白原、VIII因子相关抗原及β-血小板球蛋白）。治疗结果显示，MXJP可提高胃癌患者1年、1.5年及2年生存率，其中对IV期胃癌患者提高1年生存率效果明显（P<0.05），并降低舌质阴性率（P<0.001）。胃癌患者的抗凝血酶III、纤维连接蛋白、纤维蛋白原、VIII因子相关抗原及β-血小板球蛋白指标均有改善（P<0.05）。结果表明，MXJP可增强机体抗凝血纤溶能力，活血化瘀，进一步提高患者生存率。MXJP近期疗效较好。
